Login
$NOVT
$114.40 +$0.00 (0.0%) After hours

$NOVT 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

BOSTON, November 9, 2026 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2026.

05 Aug 2026 8-K: Results of Operations and Financial Condition

BOSTON, August 5, 2026 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2026.

27 Jul 2026 8-K: Completion of Acquisition or Disposition of Assets; Creation of a Direct Financial Obligation +1 more

BOSTON, July 27, 2026 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today announced that it has completed the acquisition of Riverpoi...

09 Jun 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 8, 2026, by and among Novanta Inc., a company continued and existing under the laws of the Province of New Brunswick, Canada (the “Company”), and each of the entit...

09 Jun 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This EQUITY PURCHASE AGREEMENT (this “Agreement”), dated as of June 8, 2026, is entered into by and among: (i) Runway Midco, LLC, a Delaware limited liability company (“Seller”); (ii) Runway Buyer, LLC, a Delaware limited liability compa...

29 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 28, 2026, Novanta Inc. (the “Company”) held its annual general meeting of shareholders (“Annual Meeting of Shareholders”). A total of 33,371,777 common shares were present or represented by proxy at the meeting, representing appro...

15 May 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This SECOND AMENDMENT TO FOURTH AMENDED AND RESTATED CREDIT AGREEMENT dated as of May 15, 2026 (this “Amendment”) is made by and among NOVANTA CORPORATION, a Michigan corporation (the “Lead Borrower”), NOVANTA UK INVESTMENTS HOLDING LIMI...

11 May 2026 8-K: Results of Operations and Financial Condition

BOSTON, May 11, 2026 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2026.

23 Feb 2026 8-K: Results of Operations and Financial Condition

BOSTON, February 23, 2026 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and f...

01 Dec 2025 8-K: Regulation FD Disclosure

Effective December 1, 2025, Novanta Inc. (the “Company”) appointed Alexander Manganiello as General Counsel and Corporate Secretary. In this role, Mr. Manganiello will lead the Company’s global legal, regulatory, corporate secretary, and...

13 Nov 2025 8-K: Regulation FD Disclosure

Novanta Inc. (“Novanta” or the “Company”) revised certain fourth quarter and full year 2025 financial guidance to reflect the completion of the recent equity issuance. The updated non-GAAP adjusted diluted earnings per share (“Adjusted D...

12 Nov 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This FIRST AMENDMENT TO FOURTH AMENDED AND RESTATED CREDIT AGREEMENT dated as of November 5, 2025 (this “Amendment”) is made by and among NOVANTA CORPORATION, a Michigan corporation (the “Lead Borrower”), NOVANTA UK INVESTMENTS HOLDING L...

03 Nov 2025 8-K: Results of Operations and Financial Condition

BOSTON, November 3, 2025 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2025.

18 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

On September 15, 2025, Barbara Hulit resigned as a member of the Board of Directors (the “Board”) of Novanta Inc. (the “Company”) and the Audit Committee and Environmental, Social and Governance Committee of the Board, effective November...

18 Sep 2025 8-K: Other Events

On September 18, 2025, the Novanta Inc. (the "Company") issued a press release announcing that its Board of Directors (the "Board") authorized the repurchase of up to an additional $200.0 million of the Company’s outstanding common share...

05 Aug 2025 8-K: Results of Operations and Financial Condition

BOSTON, August 5, 2025 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2025.

11 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

On July 8, 2025, Novanta Inc. (the “Company”) announced that Michele D. Welsh, General Counsel and Corporate Secretary of the Company, would no longer serve in those positions, effective on July 18, 2025, or such earlier date as may be a...

02 Jul 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

DOCPROPERTY DocXDocID DMS=InterwovenIManage Format=<<NUM>>v<<VER>> PRESERVELOCATION \* MERGEFORMAT 12849785v2

09 Jun 2025 8-K: Costs Associated with Exit or Disposal Activities

On June 3, 2025, Novanta Inc. (the “Company”) committed to a restructuring plan (the “2025 Restructuring Plan”) to streamline operations and align with long-term goals. The 2025 Restructuring Plan includes measures to regionalize manufac...

02 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 29, 2025, Novanta Inc. (the “Company”) held its annual general meeting of shareholders (“Annual Meeting of Shareholders”). A total of 33,915,355 common shares were present or represented by proxy at the meeting, representing appro...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support